Trial · NCT01815840
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Percent Change From Baseline in the Number of Clinically Evident Basal Cell Carcinomas at Week 73 (After 72 Weeks of Treatment) | Baseline; Week 73 | The total number of clinically evident basal cell carcinomas = the total number of target and/or non-target lesions present in individual participants. |
| Secondary | Percentage of Participants Who Discontinued Study Treatment Due to Tolerability Issues | Baseline to Week 73 | The percentage of participants who discontinued study treatment (due either to adverse event, refusal of treatment, or withdrawal of consent) was summarized by treatment group. |
| Secondary | Mean Percent Change From Baseline in Total Size of Three Target Basal Cell Carcinoma Lesions in Individual Participants at Week 73 | Baseline; Week 73 | The three target basal cell carcinoma lesions = the three largest visible lesions, at least 5 mm in the longest diameter, in individual participants. |
| Secondary | Percentage of Participants With at Least 50% Reduction in the Number of Basal Cell Carcinomas at Week 73 | Baseline; Week 73 | |
| Secondary | Percentage of Participants With New Basal Cell Carcinomas at Week 73 | Baseline; Week 73 | |
| Secondary | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 85 (12 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 85 | |
| Secondary | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 97 (24 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 97 | |
| Secondary | Percent Change in Total Number of Basal Cell Carcinomas Relative to Baseline at Week 125 (52 Weeks Following End of Treatment) (Recurrence Rate) | Baseline; Week 125 | |
| Secondary | Percentage of Participants Experiencing Any Adverse Event | Up to 125 weeks | |
| Secondary | Percent Change From Baseline in the Skindex-16 Symptom Domain Score at Week 73 | Baseline; Week 73 | The Skindex-16 is a patient-reported outcome health questionnaire. Participants were asked about their symptoms, and their answers were combined into a composite Symptom Domain Score. Scores range from 0 ("never bothered") to 100 ("always bothered"). |
| Secondary | Percent Change From Baseline in the Skindex-16 Emotion Domain Score at Week 73 | Baseline; Week 73 | The Skindex-16 is a patient-reported outcome health questionnaire. Participants were asked about their emotional state, and their answers were combined into a composite Emotion Domain Score. Scores range from 0 ("never bothered") to 100 ("always bothered"). |
| Secondary | Percent Change From Baseline in the Skindex-16 Function Domain Score at Week 73 | Baseline; Week 73 | The Skindex-16 is a patient-reported outcome health questionnaire. Participants were asked about their ability to function, and answers were combined into a composite Function Domain Score. Scores range from 0 ("never bothered") to 100 ("always bothered"). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01815840/registered